Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Prostate cancer. Found 50 abstracts

paginate
Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys. 2019 Feb;103(2):335-43.   PMCID: PMC6368223
Gershman B, Maroni P, Tilburt JC, Volk RJ, Konety B, Bennett CL, Kutikov A, Smaldone MC, Chen V, Kim SP. A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World journal of urology. 2019 Oct;37(10):2099-108.
Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM. Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials. Int J Radiat Oncol Biol Phys. 2019 Aug;104(5):1057-65.   PMCID: PMC6646073
Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiother Oncol. 2019 Sep 17;.
Joshi SS, Handorf ER, Sienko D, Zibelman M, Uzzo RG, Kutikov A, Horwitz EM, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer. European urology oncology. 2019 Jul 17;.
Karpova Y, Wu C, Divan A, McDonnell ME, Hewlett E, Makhov P, Gordon J, Ye M, Reitz AB, Childers WE, Skorski T, Kolenko V, Tulin AV. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochemical pharmacology. 2019 Sep;167:149-62.   PMCID: PMC6702078
Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJ, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadalo L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems M, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MW, Helderman van den Enden A, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon YC, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Ronlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 Sep 16;76(6):831-42.   PMCID: PMC6880781
Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer. Urol Oncol. 2019 Oct;37(10):688-95.
Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2019 Apr 13;.
Tagai EK, Miller SM, Kutikov A, Diefenbach MA, Gor RA, Al-Saleem T, Chen DY, Fleszar S, Roy G. Prostate Cancer Patients' Understanding of the Gleason Scoring System: Implications for Shared Decision-Making. Journal of cancer education : the official journal of the American Association for Cancer Education. 2019 Jan 15;34(3):441-5.   PMCID: PMC6557691
Kim AH, Konety B, Chen Z, Schumacher F, Kutikov A, Smaldone M, Abouassaly R, Khanna A, Kim SP. Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer. Urology. 2018 Oct;120:173-9.
Oliver JS, Allen RS, Eichorst MK, Mieskowski L, Ewell PJ, Payne-Foster P, Ragin C. A pilot study of prostate cancer knowledge among African American men and their health care advocates: implications for screening decisions. Cancer causes & control : CCC. 2018 Jul;29(7):699-706.   PMCID: PMC6301016
Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE. Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. European urology oncology. 2018 Sep;1(4):325-37.   PMCID: PMC6241309
Warner WA, Lee TY, Fang F, Llanos AA, Bajracharya S, Sundaram V, Badal K, Sookdeo VD, Roach V, Lamont-Greene M, Ragin C, Slovacek S, Ramsoobhag K, Brown J, Rebbeck TR, Maharaj R, Drake BF. The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer causes & control : CCC. 2018 Jul;29(7):685-97.   PMCID: PMC5999193
Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer. 2018 Apr;16(2):e315-e322.   PMCID: PMC5975965
Dubey B, Jackson M, Zeigler-Johnson C, Devarajan K, Flores-Obando RE, McFarlane-Anderson N, Tulloch-Reid M, Aiken W, Kimbro K, Jones D, Kidd LR, Ragin C. Inflammation polymorphisms and prostate cancer risk in Jamaican men: Role of obesity/body size. Gene. 2017 Sep 10;636:96-102.   PMCID: PMC5645041
Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 Apr;35(4):125-34.
Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 Apr;35(4):125-34.
Turner RM, Yecies TS, Yabes JG, Ristau BT, Woldemichael E, Davies BJ, Jacobs BL, Nelson JB. Biopsy Perineural Invasion in Prostate Cancer Patients Who Are Candidates for Active Surveillance by Strict and Expanded Criteria. Urology. 2017 Apr;102:173-7.   PMCID: PMC5376357
Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016 Nov;121(2):294-8.
O'Malley DM, Hudson SV, Ohman-Strickland PA, Bator A, Lee HS, Gundersen DA, Miller SM. Follow-up Care Education and Information: Identifying Cancer Survivors in Need of More Guidance. Journal of Cancer Education. 2016 Mar;31(1):63-9.   PMCID: PMC4475492
Shaikh T, Wang L, Ruth K, Hallman M, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2016 Jan 29;15(2):156-62.   PMCID: PMC4789160
Zaorsky NG, Shaikh T, Murphy CT, Hallman MA, Hayes SB, Sobczak ML, Horwitz EM. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev. 2016 Jun 17;48:50-60.
Aiken WD, Jones KS, Ragin C, James K. Rural-urban differences in the clinico-pathologic profiles of Jamaican men with prostate cancer. Infect Agent Cancer. 2015 Jan;10:32.   PMCID: 4584435
Hall MJ, Ruth KJ, Chen DY, Gross LM, Giri VN. Interest in genomic SNP testing for prostate cancer risk: a pilot survey. Hered Cancer Clin Pract. 2015 Jan;13(1):11.   PMCID: 4396119
Haseebuddin M, Smaldone MC. Treatment of localized prostate cancer in elderly patients. Gland Surg. 2015 Aug;4(4):283-7.   PMCID: PMC4523629
Martin JM, Handorf EA, Price RA, Cherian G, Buyyounouski MK, Chen DY, Kutikov A, Johnson ME, Ma CC, Horwitz EM. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. Medical Dosimetry. 2015 Jan;40(3):186-9.   PMCID: 4500753
Miller SM, Hudson SV, Hui SK, Diefenbach MA, Fleisher L, Raivitch S, Belton T, Roy G, Njoku A, Scarpato J, Viterbo R, Buyyounouski M, Denlinger C, Miyamoto C, Reese A, Baman J. Development and preliminary testing of PROGRESS: a Web-based education program for prostate cancer survivors transitioning from active treatment. Journal of Cancer Survivorship. 2015 Sep;9(3):541-53.   PMCID: 4537811
Shaikh T, Zaorsky NG, Ruth K, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. Brachytherapy. 2015 Jan;14(3):316-21.   PMCID: 4424094
Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015 May 28;115(3):295-300.
Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK. Does family history of prostate cancer affect outcomes following radiotherapy?. Radiotherapy and Oncology. 2014 Feb;110(2):229-34.   PMCID: 3991234
Handorf E, Crumpler N, Gross L, Giri VN. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal of Genetic Counseling. 2014 Jun;23(3):371-6.   PMCID: PMC4028414
Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy. 2014 Sep;13(5):456-64.
Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan;11(1):6-19.   PMCID: not NIH funded
Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(3):E433-E439.   PMCID: not NIH funded
Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. OLDER AGE PREDICTS DECREASED METASTASIS AND PROSTATE CANCER-SPECIFIC DEATH FOR MEN TREATED WITH RADIATION THERAPY: META-ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1293-301.   PMCID: NIHMS285956
Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):445-52.   PMCID: PMC2952349
Sharma NK, Li TY, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):437-44.   PMCID: PMC2909627
Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Menard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radation therapy for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2010 Feb;76(2):361-8.   PMCID: PMC2847420
Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Dec;78(5):1314-22.   PMCID: PMCID: PMC2920356 [Available on 2011/12/1]
Sharma NK, Cohen RJ, Eade TN, Buyyounouski MK, Uzzo RG, Li JS, Crawford K, Chen DY, McNeeley S, Horwitz EM. An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. Brachytherapy. 2010 Apr;9(2):126-30.   PMCID: not NIH funded
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiotherapy and Oncology. 2010 Jul;96(1):6-12.   PMCID: Not required
Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating Tumor Cells: Evolving Evidence and Future Challenges. The oncologist. 2009 Jan;14(11):1070-82.   PMCID: not NIH funded
Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2009 Jun;74(2):383-7.   PMCID: PMC2905150
Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. ACR Appropriateness Criteria (R) on External Beam Radiation Therapy Treatment Planning for Clinically Localed Prostate Cancer Expert Panel on Radiation Oncology-Prostate. International Journal of Radiation Oncology Biology Physics. 2009 Jul;74(3):667-72.
Zhang M, Ho A, Hammond EH, Suzuki Y, Bermudez RS, Lee RJ, Pilepich M, Shipley WU, Sandler H, Khor LY, Pollack A, Chakravarti A. Prognostic value of surviving in locally advanced prostate cancer: study based on RTOG 8610. International Journal of Radiation Oncology Biology Physics. 2009 Mar;73(4):1033-42.   PMCID: PMC 2678565
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology. 2008 Oct;54(4):816-24.
Horwitz EM. Does addition of 6 months' androgen suppression to radiotherapy prolong survival of men with prostate cancer?. Nature Clinical Practice Urology. 2005 Jan;2(1):16-7.
Xiong W, Li J, Ma CM. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer. Physics in Medicine and Biology. 2005 Jan;50(7):1483-92.
Hanks GE, Krall JM, Pilepich MV, Asbell SO, Perez CA, Rubin P, Sause WT, Doggett RL. Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: Implications of RTOG data for patient management and trial design and stratification. International Journal of Radiation Oncology Biology Physics. 1992 Jan;23(2):293-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Prostate cancer

Prostate cancer Brachytherapy Radiation therapy Radiotherapy phase-iii trial radiotherapy Radiation Clinical trials Male Prostatic Neoplasms THERAPY neoadjuvant prostate cancer radical prostatectomy Breast cancer TRIAL Radiotherapy Dosage Cytoreduction Treatment of primary tumor adjuvant Dosimetry androgen deprivation Family history Quality of life Prognostic factors Survivorship Prostatectomy competing risk Technology Treatment Outcome methods locally advanced-carcinoma Cancer survival Hormonal therapy external-beam radiotherapy androgen suppression Surgery in metastatic Radical prostatectomy Local treatment Quality assurance radiation-therapy Prostate Surgery in systemic carcinoma Cytoreductive radical prostatectomy Shared decision-making po-2 Low-dose-rate brachytherapy SECONDARY ANALYSIS local recurrence Cancer screening antigen secondary Early detection of cancer Genetic mutations Sleeved seeds risk Tumors IN-VIVO LDR Intraoperative planning Patient variation Upgrading antiandrogen Facility volume African American local-control migration External beam radiation therapy randomized trial adjuvant radiotherapy Colon cancer analysis level Hypofractionated Cost-effectiveness local therapy blood T4 Dose escalation DEPRIVATION Volumetric-modulated arc therapy Perineural invasion interstitial-brachytherapy Adult Gleason score INTENSITY-MODULATED RADIOTHERAPY Distant metastasis GASTRIC CARCINOMAS HEPATOCELLULAR-CARCINOMA Middle Aged Oncology dosimetric analysis surgery Chemotherapy Prostate cancer knowledge Gleason grade group 5 Radiotherapy dose fractionation Lymph node evaluation Salvage low dose rate brachytherapy ORGAN MOTION progression-free algorithm Waist to hip ratio Outcomes IRRADIATION Testis BODY-COMPOSITION Risk assessment Rural SPLICE VARIANTS patient care Fractionation lymph node Cancer in populations of African ancestry Radical Prostatectomy Genetics & Heredity Androgen suppression hormonal-therapy CONFORMAL RADIOTHERAPY Parameter estimation Postoperative Parp-1 Lymphography Training Trinidad and Tobago radiation Target volumes Radiation Absorption CLINICAL TARGET VOLUME ASSOCIATION BRCA1 MESSENGER-RNA definitive radiotherapy Personalized medicine Intensity-modulated radiotherapy CARRIERS Radiation Exposure Brca1 CARCINOMA hypofractionation Serum testosterone Radiation Protection quality Tumor microenvironment replacement therapy conformal radiation-therapy survival Poly(ADP-ribose) predict pathological stage
Last updated on Friday, December 06, 2019